Boost Your Bottom Line: CPT Code Updates for NGS RCM
Join us for an in-depth exploration of the latest CPT codes and their potential impact on your organization’s reimbursement rates. Discover the latest trends in NGS reimbursement, gain insights into the Medicare Gapfill process, and learn practical strategies to optimize your revenue cycle. We’ll also highlight how Velsera’s innovative solutions can help maximize reimbursement and streamline your RCM workflow, ensuring your organization stays ahead in the ever-evolving healthcare landscape.
Key Takeaways:
- How the 2024 and beyond CPT code updates will affect NGS billing for both somatic and soon germline GSP codes
- Changes in biomarker laws and how they can impact laboratories
- MolDX expansion, updates, and requirements for Technical Assessments and Z-Codes
Meet the speaker:
Sarah Overton,
Director, Revenue Cycle Management
Sarah has over 20 years of healthcare industry experience working for multiple Fortune 500 companies including Cardinal Health and Novartis. Most recently Sarah has over 15 years in NGS, with a focus on oncology diagnostics and specializing in revenue cycle management including billing, collections, market access and reimbursement. Sarah has led multiple RCM teams at laboratories including Genoptix, Adaptive Biotechnologies, Cooper Genomics and Velsera. Currently at Velsera, Sarah is the Director of Revenue Cycle Management and addresses client reimbursement needs and concerns, leading the revenue cycle management team and overseeing Velsera’s RCM Services offering with a focus on MolDX and Technical Assessments and maximizing laboratory revenue.